版本:
中国

BRIEF-uniQure announces it will not seek marketing authorization renewal for Glybera in Europe

April 20 uniQure NV

* uniQure announces it will not seek marketing authorization renewal for Glybera in Europe

* Marketing authorization for Glybera® to expire on October 25, 2017

* Maintains focus on core programs in Hemophilia B, Huntington's Disease and congestive heart failure

* Will continue to make product available to chiesi to treat any patients that are approved for treatment prior to October 25, 2017

* Expects to reduce future expenses related to product by about $2 million annually, beginning in 2018 and net of any payments to Chiesi Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐